Merck to showcase 100+ oncology studies at 2026 ASCO meeting

Highlighting KEYTRUDA & expanding cancer pipeline

Samsung Bioepis’ Pembrolizumab biosimilar SB27 meets phase 1 PK endpoints

The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients

India and Japan deepen healthcare collaboration at 3rd joint committee meeting

Discussions focused on digital health, non-communicable diseases, resilient supply chains, medical innovation, and healthcare workforce development

India chairs first BRICS Health Working Group meet

Outlines nine priority health tracks spanning TB research, digital health, early warning systems and regulatory cooperation

Orbis India Partners Meet 2026 focuses on sustainable, climate-resilient eye care

Green Vision Centres cut emissions, expand community coverage as partners align on resilient eye health systems

Maharashtra MEMS 108 gets 1,756 new ambulances as Sumeet SSG partners Pinnacle

36 districts to get advanced ALS, BLS and neonatal ambulances under MEMS 108

Kenvue unleashes science-driven skincare offensive at American Academy of Dermatology meet

The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection

Sun Pharma to spotlight 14 dermatology studies at 2026 AAD annual meeting

The presentations underscore the company’s deep expertise in dermatology and immunology

Lonza expands manufacturing pact with Genetix to meet rising demand for gene therapy ZYNTEGLO

Moderna discontinues congenital virus program after Phase 3 trial fails to meet primary endpoint

Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target